Skip to content

Rachel F. Tyndale

6 papers in the library · 267 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.

Neuropsychopharmacology May 9, 2026 Claudia Poluga, S. S. Dheda, Nadia Boachie et al.

Cannabis withdrawal in cannabis use disorder (CUD) increase the risk of relapse and lacks effective treatments. The endocannabinoid enzyme fatty acid amide hydrolase (FAAH) may influence cannabis use and withdrawal, but the relationship between FAAH levels and withdrawal symptoms remains unclear. This study aims to investigate changes in FAAH levels during short-term abstinence from cannabis...

Designer Drugs 2.0

Clinical Pharmacology & Therapeutics January 13, 2017 Marilyn A. Huestis, Rachel F. Tyndale 12 citations

This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new pharmacotherapies and pose serious health problems. Novel...

The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.

American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics July 5, 2007 Rachel F. Tyndale, Jennifer I Payne, Alexandra L Gerber et al.

A genetic variation in fatty acid amide hydrolase (FAAH), C385A (P129T), has been previously associated with risk for problem street drug use. FAAH is a mammalian enzyme that inactivates neuromodulatory-signaling lipids including the endogenous cannabinoid 1 receptor agonist anandamide. We investigated in adult Caucasians (N = 749) whether this FAAH variant altered the risk for trying, regular...

Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.

Drug Metabolism and Disposition June 1, 2002 Wenjiang Zhang, Yamini Ramamoorthy, Rachel F. Tyndale et al. 17 citations

18-Methoxycoronaridine, a newly developed ibogaine analog, has been reported to decrease the self-administration of morphine, cocaine, ethanol, and nicotine. It has also been reported to attenuate naltrexone-precipitated signs of morphine withdrawal. In this study, three metabolites of 18-methoxycoronaridine (18-MC) were separated and identified by high-performance liquid...

DOI: 10.1124/dmd.30.6.663 (opens in new tab) Full text (opens in new tab) Drug metabolism Addiction treatment Cyp2c19 enzyme Pharmacokinetics +1

Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates

Pharmacogenetics August 1, 2001 Yamini Ramamoorthy, Rachel F. Tyndale, Edward M. Sellers 92 citations

CYP2D6 is involved in the metabolism of several classes of drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors and various amphetamines. CYP2D6*10 is an allelic variant, producing an enzyme with Pro34Ser and Ser486Thr amino acid substitutions. Approximately 75% of Asians possess the *10 allele. We sought to further characterize CYP2D6.10 catalytically in vitro in...

DOI: 10.1097/00008571-200108000-00003 (opens in new tab) MDMA Cyp2d6 Dextromethorphan Debrisoquine +7

Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.

Annals of the New York Academy of Sciences September 1, 2000 Deborah C. Mash, Craig A. Kovera, John Pablo et al. 146 citations

Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term...

DOI: 10.1111/j.1749-6632.2000.tb05213.x (opens in new tab) Full text (opens in new tab) Noribogaine Substance abuse treatment Addiction treatment Drug rehabilitation +16